Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chlamydia vaccine (Spixia Biotechnology)
- Development stage
- Discontinued
- Lead developer
- Eurocine Vaccines
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
01
Overview
The chlamydia vaccine (Spixia Biotechnology) is a prophylactic vaccine candidate designed to prevent infections caused by *Chlamydia trachomatis*. Developed through a collaboration between Spixia Biotechnology and Eurocine Vaccines, the vaccine is based on a patented recombinant polypeptide antigen discovered by Spixia. The vaccine is intended to elicit a protective immunological response against the bacterium, which is a leading cause of sexually transmitted infections and can lead to severe complications such as pelvic inflammatory disease and infertility in women. Development reached the preclinical stage, with manufacturing process development conducted by Biovian Oy. However, the program is currently classified as discontinued following corporate shifts at Eurocine Vaccines.
- Other names
- Spixia chlamydia vaccineEurocine chlamydia vaccine
02
Targets
Chlamydia trachomatis
Beyond the preview
Go deeper on chlamydia vaccine (Spixia Biotechnology).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chlamydia vaccine (Spixia Biotechnology).